Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Janah Vandenhoeck und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium. Hauptthemen laut MEDLINE: DNA Methylation, Mesothelioma, Pleural Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Tegen Kanker, Universiteit Antwerpen, Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Pleural mesothelioma (PM) is a rare and aggressive cancer that often requires multiple diagnostic procedures before a definitive diagnosis can be made. To improve diagnostic accuracy, we developed a DNA methylation‐based biomarker assay capable of distinguishing PM from healthy pleura and other pleural pathologies. Using Infinium EPIC array data, we identified 744 hypermethylated CpG sites in PM as candidate biomarkers. These were validated in silico using external datasets, yielding a high mean AUC of 0.935. Clinical validation was performed using IMPRESS, a novel bisulfite‐free methylation detection technique that enables simultaneous analysis of thousands of CpG sites. A two‐step classifier approach was applied: the first model differentiated tumoral from nontumoral pleura with 89.2% sensitivity and 93.5% specificity, while the second model distinguished PM from pleural metastases with 85.2% sensitivity and 100% specificity. These results demonstrate that our methylation‐based biomarker panel offers a highly accurate and minimally invasive tool for differentiating PM from other pleural conditions, potentially streamlining the diagnostic process and improving clinical decision‐making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium.
- Center for Oncological Research Antwerp (CORE), University of Antwerp and Antwerp University Hospital, Wilrijk, Belgium.
- Department of Pathology, Antwerp University Hospital and University of Antwerp, Edegem, Belgium.
- Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium.
- Antwerp Surgical Training, Anatomy and Research Center (ASTARC), University of Antwerp, Wilrijk, Belgium.
- Department of Thoracic Oncology, Antwerp University Hospital and University of Antwerp, Edegem, Belgium.
ORCID-Profile: Janah Vandenhoeck, Nele De Meulenaere, Joe Ibrahim, Guy Van Camp, Ken Op de Beeck
Förderung
- Stichting Tegen Kanker
- Universiteit Antwerpen
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
Vandenhoeck, J., De Meulenaere, N., Vanpoucke, T., Ibrahim, J., Peeters, D., Yogeswaran, S. K., Wen, W., Van Schil, P., Hendriks, J. M. H., Raskin, J., van Meerbeeck, J., Van Camp, G., & Op de Beeck, K. (2025). Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies. Molecular Oncology. https://doi.org/10.1002/1878-0261.70159
Vancouver
Vandenhoeck J, De Meulenaere N, Vanpoucke T, Ibrahim J, Peeters D, Yogeswaran SK, et al. Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies. Molecular Oncology. 2025. doi:10.1002/1878-0261.70159
BibTeX
@article{Vandenhoeck2025,
author = {Vandenhoeck, Janah and De Meulenaere, Nele and Vanpoucke, Thomas and Ibrahim, Joe and Peeters, Dieter and Yogeswaran, Suresh Krishan and Wen, Wen and Van Schil, Paul and Hendriks, Jeroen M H and Raskin, Jo and van Meerbeeck, Jan and Van Camp, Guy and Op de Beeck, Ken},
title = {Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70159}
}
EUVIMED